Zepbound and Mounjaro have been shown to yield greater weight loss than Wegovy or Ozempic. The dual mechanism of tirzepatide, ...

A new 'living guideline' from the American College of Physicians (ACP) recommends semaglutide (Wegovy) and tirzepatide ...

Tirzepatide is the active ingredient in an injectable medication (Zepbound) approved by the U.S. Food and Drug Administration ...

More than 10 million US patients will regain easy access to Eli Lilly & Co.’s obesity shot Zepbound through insurance after CVS Health Corp. reversed a controversial decision to restrict it for ...

Wegovy (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist medication that’s approved by the U.S. Food and ...

A recent study found that setting personal weight loss goals when using Zepbound or Mounjaro may lead to better results.

CVS Health said it will restore coverage of Eli Lilly's blockbuster weight loss injection Zepbound and start covering its new obesity pill on its standard drug plans. The move supports Lilly's efforts ...

Invitations to exclusive industry events and research by Les Luchter , June 10, 2026 ...

CVS Caremark is adding Zepbound, Eli Lilly’s obesity drug, back to its commercial insurance plan formularies, more than a year after it stopped covering it in favor of Novo Nordisk’s Wegovy.

In a reversal from last year, CVS will begin covering Eli Lilly's Zepbound and Foundayo in its standard prescription plan, a win for GLP-1 patients.